Krista A Delviks-Frankenberry

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8794345/publications.pdf

Version: 2024-02-01

33 papers 1,800 citations

279798 23 h-index 395702 33 g-index

34 all docs 34 docs citations

34 times ranked 1906 citing authors

#	Article	IF	Citations
1	Targeting natural splicing plasticity of APOBEC3B restricts its expression and mutagenic activity. Communications Biology, 2021, 4, 386.	4.4	7
2	Crystal Structure of a Soluble APOBEC3G Variant Suggests ssDNA to Bind in a Channel that Extends between the Two Domains. Journal of Molecular Biology, 2020, 432, 6042-6060.	4.2	12
3	Structural Insights into APOBEC3-Mediated Lentiviral Restriction. Viruses, 2020, 12, 587.	3.3	22
4	Development of Lentiviral Vectors for HIV-1 Gene Therapy with Vif-Resistant APOBEC3G. Molecular Therapy - Nucleic Acids, 2019, 18, 1023-1038.	5.1	15
5	Authentication Analysis of MT-4 Cells Distributed by the National Institutes of Health AIDS Reagent Program. Journal of Virology, 2019, 93, .	3.4	11
6	Crystal structure of the catalytic domain of HIV-1 restriction factor APOBEC3G in complex with ssDNA. Nature Communications, 2018, 9, 2460.	12.8	58
7	Dynamics and regulation of nuclear import and nuclear movements of HIV-1 complexes. PLoS Pathogens, 2017, 13, e1006570.	4.7	93
8	Minimal Contribution of APOBEC3-Induced G-to-A Hypermutation to HIV-1 Recombination and Genetic Variation. PLoS Pathogens, 2016, 12, e1005646.	4.7	44
9	Multiple APOBEC3 Restriction Factors for HIV-1 and One Vif to Rule Them All. Journal of Molecular Biology, 2014, 426, 1220-1245.	4.2	188
10	Xenotropic MLV envelope proteins induce tumor cells to secrete factors that promote the formation of immature blood vessels. Retrovirology, 2013, 10, 34.	2.0	3
11	Connection subdomain mutations in HIV-1 subtype-C treatment-experienced patients enhance NRTI and NNRTI drug resistance. Virology, 2013, 435, 433-441.	2.4	11
12	Generation of Multiple Replication-Competent Retroviruses through Recombination between PreXMRV-1 and PreXMRV-2. Journal of Virology, 2013, 87, 11525-11537.	3.4	12
13	Characterization, Mapping, and Distribution of the Two XMRV Parental Proviruses. Journal of Virology, 2012, 86, 328-338.	3.4	26
14	Biochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase. Nucleic Acids Research, 2012, 40, 345-359.	14.5	14
15	Recombinant origin, contamination, and de-discovery of XMRV. Current Opinion in Virology, 2012, 2, 499-507.	5.4	31
16	Mechanisms and Factors that Influence High Frequency Retroviral Recombination. Viruses, 2011, 3, 1650-1680.	3.3	62
17	Phenotypic characterization of drug resistance-associated mutations in HIV-1 RT connection and RNase H domains and their correlation with thymidine analogue mutations. Journal of Antimicrobial Chemotherapy, 2011, 66, 702-708.	3.0	29
18	Lack of Detection of Xenotropic Murine Leukemia Virus-Related Virus in HIV-1 Lymphoma Patients. Advances in Virology, 2011, 2011, 1-4.	1.1	6

#	Article	IF	CITATIONS
19	Severe Restriction of Xenotropic Murine Leukemia Virus-Related Virus Replication and Spread in Cultured Human Peripheral Blood Mononuclear Cells. Journal of Virology, 2011, 85, 4888-4897.	3.4	24
20	Recombinant Origin of the Retrovirus XMRV. Science, 2011, 333, 97-101.	12.6	220
21	Inhibition of Xenotropic Murine Leukemia Virus-Related Virus by APOBEC3 Proteins and Antiviral Drugs. Journal of Virology, 2010, 84, 5719-5729.	3.4	74
22	P Body-Associated Protein Mov10 Inhibits HIV-1 Replication at Multiple Stages. Journal of Virology, 2010, 84, 10241-10253.	3.4	145
23	A Novel Molecular Mechanism of Dual Resistance to Nucleoside and Nonnucleoside Reverse Transcriptase Inhibitors. Journal of Virology, 2010, 84, 5238-5249.	3.4	44
24	The "Connection―Between HIV Drug Resistance and RNase H. Viruses, 2010, 2, 1476-1503.	3.3	39
25	Subtype-Specific Differences in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Connection Subdomain of CRF01_AE Are Associated with Higher Levels of Resistance to $3\hat{a}\in^2$ -Azido- $3\hat{a}\in^2$ -Deoxythymidine. Journal of Virology, 2009, 83, 8502-8513.	3.4	29
26	Real-Time PCR Analysis of HIV-1 Replication Post-entry Events. Methods in Molecular Biology, 2009, 485, 55-72.	0.9	66
27	HIV-1 reverse transcriptase connection subdomain mutations reduce template RNA degradation and enhance AZT excision. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 10943-10948.	7.1	57
28	Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido-3'-deoxythymidine resistance. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 317-322.	7.1	126
29	Mutations in Human Immunodeficiency Virus Type 1 RNase H Primer Grip Enhance 3′-Azido-3′-Deoxythymidine Resistance. Journal of Virology, 2007, 81, 6837-6845.	3.4	78
30	Antiretroviral Drug Resistance Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Increase Template-Switching Frequency. Journal of Virology, 2004, 78, 8761-8770.	3.4	70
31	Structural Determinants of Murine Leukemia Virus Reverse Transcriptase That Affect the Frequency of Template Switching. Journal of Virology, 2000, 74, 7171-7178.	3.4	73
32	Effect of Distance between Homologous Sequences and 3′ Homology on the Frequency of Retroviral Reverse Transcriptase Template Switching. Journal of Virology, 1999, 73, 7923-7932.	3.4	51
33	Psi- vectors: murine leukemia virus-based self-inactivating and self-activating retroviral vectors. Journal of Virology, 1997, 71, 6218-6224.	3.4	60